A Phase 4 interventional study of Simvastatin 10mg and Ezetimibe 10mg in Diabetes Mellitus, Type 2, sponsored by The University of Hong Kong. Enrolling by invitation at 1 site in Hong Kong. Open to female participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-11-28.
Sponsored by The University of Hong Kong · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing simvastatin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Simvastatin · Diabetes Mellitus, Type 2.
Among the 19 studies testing simvastatin in Diabetes Mellitus, Type 2, this one is the 4th largest by planned enrollment, is the only one that started in 2022, is one of 4 in phase 4, and was the 18th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 19 studies testing simvastatin in Diabetes Mellitus, Type 2 is open now, in 1 country.
By country, each count listing its studies:
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 50 Years to 74 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 33 across the 19 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
20 studies in Diabetes Mellitus, Type 2 by The University of Hong Kong: 5 open now, 6 under way, none of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 20 studies in Diabetes Mellitus, Type 2 by The University of Hong Kong, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 16th registered.
The University of Hong Kong’s Diabetes Mellitus, Type 2 studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing simvastatin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among The University of Hong Kong’s 20 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the impact of simvastatin on the bone density of postmenopausal women with type 2 diabetes over a duration of 18 months, using a randomized controlled trial design. Aiming to recruit 240 patients, half of them will be randomly assigned to receive simvastatin treatment, while the other half will receive ezetimibe, also a lipid-lowering agent with no known effect on bone. Bone density will be measured at the baseline and the end of the study for comparison of the changes between the simvastatin and the ezetimibe groups.
This is an investigator-initiated study. The principal investigator and the study team will be responsible for ensuring that the study is conducted in compliance with this protocol and the study data collected are verified against the relevant source documents.
All participants will undergo clinical and biochemical assessments at baseline of the trial. Participants will be seen by an endocrinologist at baseline and subsequent follow-up visits at 3, 6, 12 and 18 months respectively.
Study Procedures and Assessments Screening Procedures
Patients will be recruited from medical out-patient clinics, mainly from the primary health care clinics, in the Hong Kong West Cluster of the Hong Kong Hospital Authority. Consecutive participants who fulfil the inclusion and exclusion criteria are invited to participate in this randomized controlled trial after obtaining informed consent.
Clinical and biochemical assessments
Participants will attend a clinical assessment session at baseline after an overnight fast for at least 8 hours. Demographic data and medical history will be obtained using a standardized questionnaire. Personal and family history of fragility fractures (spine, hip, humerus, wrist and ankle) will be recorded. Important clinical risk factors of osteoporosis will be evaluated, including smoking, drinking, family history of fragility fractures, parental history of hip fractures, prior use and duration of hormonal replacement therapy, and levels of physical activity. The levels of physical activity will be assessed through the International Physical Activity Questionnaire (IPAQ). Daily calcium intake will be assessed using a semi-quantitative questionnaire. Body weight, body height and blood pressure (BP) will be measured. Hypertension is defined as BP ≥140/90 mmHg or the use of antihypertensive medications.
Fasting blood will be drawn for plasma glucose, HbA1c, insulin, lipid profile, albumin, calcium, phosphate, creatinine levels and eGFR. Patients with 25OHD levels \<50 nmol/L will be given additional cholecalciferol 1000 units/day for 8 weeks followed by reassessment of 25-hydroxyvitamin D (25OHD) to ensure repletion.
Follow-up visits (3, 6, 12, 18 months after baseline visit)
During each follow-up visits, participants will have fasting blood tests checked for liver and renal function tests, creatine kinase, calcium and phosphate, fasting glucose, HbA1c and lipid profile.
Glycaemic control will be managed according to the standard of care. During follow-up visits, tolerance to lipid-lowering therapy will be assessed. Persistent elevation of liver enzymes (alanine aminotransferase and aspartate aminotransferase) to >3 times the upper limit of normal, increase in creatine kinase with clinical signs and symptoms of muscle involvement, or drug intolerance will be excluded from the trial.
During follow-up visits, participants may have changes in clinical conditions and thus be indicated for anti-osteoporosis therapy, or higher-intensity statin. Those who develop incident hip or vertebral fractures, or osteoporosis, and thus require anti-osteoporosis therapy, will be excluded from the trial. Those who develop incident atherosclerotic cardiovascular disease, and thus require higher intensity statin, will also be excluded from the trial.
Withdrawal from study
Patients are informed orally and in writing that they are free to withdraw their participation in the study without bias or prejudice. A patient who decides to stop all therapeutic interventions will be followed by the clinical team for the usual medical care. The date of withdrawal and reason for discontinuation, if known, will be recorded in the medical record.
Statistical Analyses
All statistical analyses will be performed with using R package or IBM® SPSS® version 26. Data will be presented as mean± standard deviation (SD), 95% confidence interval (CI), median with 25th-75th percentile, and number with percentage as appropriate.
All analyses described in this section will be performed based on intention-to-treat analysis and repeated for the per-protocol analysis. Data not normally distributed will be logarithmically transformed before analysis. Between-group comparisons are done with t-test or Mann-Whitney U test for continuous data, and chi-square or Fisher exact test for categorical variables. Two-sided p-value \<0.05 will be considered statistically significant.
Baseline demographics and anthropometric parameters (age, BMI), laboratory parameters (HbA1c, LDL-cholesterol, serum creatinine), bone health assessment, including bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers and fracture risk assessment (FRAX) score, clinical risk factors of osteoporosis, family history of fragility fractures (partly reflecting involvement of genetics in bone health), and concomitant medications (various classes of anti-hypertensives and anti-diabetic agents) will be compared between simvastatin and ezetimibe arms.
If applicable, adjustments for covariates may be employed in Analysis of Covariance (ANCOVA). Any adjustments will be pre-specified in the description of the analysis.
BMD is measured with a dual-energy X-ray absorptiometry (DXA) machine (Hologic QDR 4500, Waltham, MA, USA). BMD change over the 18-month period will be calculated for each participant. The BMD change over the lumbar spine (LS), femoral neck (FN), total hip (TH) and distal radius from baseline will be the dependent variable in the ANCOVA model.
Sample size calculation
Sample size calculation is performed with R package (1). According to the study on the impact of lovastatin on TH BMD by Safaei et al. (2), a difference in BMD change over 18-month study period between lovastatin-treated and control groups was 0.098 g/cm2 for TH, with a pooled standard deviation of 0.13 g/cm2. The estimated effect size of TH BMD change over the 18-month study period is 0.75 (95% CI: 0.2-1.3). Assuming the lower CI for the estimated effect size of 0.2, the study would require a sample size of 96 in each group (i.e. total sample size of 192), to achieve 90% power and a level of significance of 5%, for declaring that simvastatin is superior to the active comparator at a 0.02 g/cm2 margin of superiority. To ensure an analysis size of 96 individuals, an overall sample size of 120 individuals per treatment arm will be recruited, anticipating a drop-out rate of approximately 20%.
Protocol Deviations
Protocol deviations are defined as any instance in which the patient or clinical team does not perform scheduled activities/tasks such as missed visits and missed tests and evaluations. Protocols deviations will be reported on the patient's chart.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One simvastatin 10mg-tablet and one placebo tablet with the shape of ezetimibe 10mg each day.
Drug: Simvastatin 10mg
One ezetimibe 10mg-tablet and one placebo tablet with the shape of simvastatin 10mg each day.
Drug: Ezetimibe 10mg
One simvastatin 10mg-tablet
One ezetimibe 10mg-tablet
The change in the TH BMD after 18 months of simvastatin compared with ezetimibe
BMD at the TH will be measured with DXA and compared.
Time frame: Screening visit and Visit 5 (18 month after baseline visit)
The changes in the LS BMD after 18 months of simvastatin compared with ezetimibe
BMD at the LS will be measured with DXA and compared.
Time frame: Screening visit and Visit 5 (18 month after baseline visit)
The changes in the FN BMD after 18 months of simvastatin compared with ezetimibe
BMD at the FN will be measured with DXA and compared.
Time frame: Screening visit and Visit 5 (18 month after baseline visit)
The changes in BMD over distal radius after 18 months of simvastatin compared with ezetimibe
BMD at the distal radius will be measured with DXA and compared.
Time frame: Screening visit and Visit 5 (18 month after baseline visit)
The changes in bone turnover marker, carboxy-terminal cross-linked telopeptide of type 1 collagen (CTX) after 6 months and 18 months of simvastatin compared with ezetimibe
Time frame: Baseline visit, Visit 3 (6 months after Baseline visit) and Visit 5 (18 months after Baseline visit)
The changes in bone turnover marker, amino-terminal propeptides of type 1 collagen (P1NP) after 6 months and 18 months of simvastatin compared with ezetimibe
Time frame: Baseline visit, Visit 3 (6 months after Baseline visit) and Visit 5 (18 months after Baseline visit)
The changes in TBS after 18 months of simvastatin compared with ezetimibe
A higher TBS indicates better quality of bone which is less likely to fracture. The minimum value of TBS is 0.8, while the maximum value of TBS is 1.6.
Time frame: Screening visit and Visit 5 (18 month after baseline visit)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Apr 2022 (actual). Primary completion is estimated for Dec 2024, 32 months after the start.
Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 32 months is close to that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simvastatin